Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 35Pancreatic Fistula 4Pancreatic Ductal Adenocarcinoma 2Bile Duct Neoplasms 2Recurrence 1Peritoneal Diseases 1Periampullary Cancer 1Pancreatitis, Chronic 1Pancreatic Adenocarcinoma 1Obesity 1Neoplasm Metastasis 1Metabolic Syndrome 1Locally Advanced Pancreatic Adenocarcinoma 1Jaundice, Obstructive 1Hypoxia 1Hemorrhage 1Gastrointestinal Stromal Tumor of Duodenum 1Diabetes Mellitus 1Cholangiocarcinoma 1Carcinoma, Pancreatic Ductal 1Adenocarcinoma 1

Interventions

Hyperthermic Intraperitoneal Chemotherapy 2Pancreaticoduodenectomy 1Mitomycin 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Peritoneal Diseases × Pancreaticoduodenectomy × Gastrointestinal × Clear all
NCT02850874 2022-04-27

HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma

Wake Forest University Health Sciences

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Neoplasms, Peritoneal Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡